60 Degrees Pharmaceuticals (SXTP) Cash from Financing Activities (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Cash from Financing Activities of $3.4 million for Q1 2026, up 98.58% year-over-year from $1.7 million in Q1 2025, and up 634.77% quarter-over-quarter from $458614.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Cash from Financing Activities (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Cash from Financing Activities for 5 consecutive years, with $3.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 98.58% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $8.1 million (up 18.45% YoY), while the FY2025 annual figure was $6.4 million, down 8.73% from the prior year.
- Cash from Financing Activities advanced to $3.4 million in Q1 2026 per SXTP's latest filing, from $458614.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $6.0 million in Q3 2023 and bottomed at -$68629.0 in Q4 2022.
- Historically, Cash from Financing Activities has averaged $1.9 million across 5 years, with a median of $1.1 million in 2025.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities tumbled 100.27% — and 2025, when it jumped 47034.02%.
- 60 Degrees Pharmaceuticals' Cash from Financing Activities stood at -$68629.0 in 2022, then jumped by 8800.56% to $6.0 million in 2023, then slumped by 99.98% to $973.0 in 2024, then surged by 47034.02% to $458614.0 in 2025, then surged by 634.77% to $3.4 million in 2026.
- Business Quant data shows SXTP's Cash from Financing Activities at $3.4 million in Q1 2026, $458614.0 in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.37 Mn |
| Mar 31, 2026 | 3.37 Mn |
| Dec 31, 2025 | 458,614.00 |
| Dec 31, 2025 | 458,614.00 |
| Sep 30, 2025 | 4.28 Mn |
| Sep 30, 2025 | 4.28 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | 973.00 |
| Dec 31, 2024 | 973.00 |
| Sep 30, 2024 | 5.15 Mn |
| Sep 30, 2024 | 5.15 Mn |
| Jun 30, 2024 | -865.00 |
| Jun 30, 2024 | -865.00 |
| Mar 31, 2024 | 1.90 Mn |
| Mar 31, 2024 | 1.90 Mn |
| Sep 30, 2023 | 5.97 Mn |
| Sep 30, 2023 | 5.97 Mn |
| Jun 30, 2023 | 321,068.00 |
| Jun 30, 2023 | 321,068.00 |